Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership ...

The researchers found 25.6 million people aged 15 to 49 years had new HSV-2 infections and 519.5 million (13.3%) had existing (prevalent) HSV-2 infections globally in 2020. (HealthDay News) — The ...

A photomicrograph image of herpes virus antibodies detected using immunofluorescent staining technique, 1977. Image courtesy CDC/Dr. Craig Lyerla. (Photo by Smith Collection/Gado/Getty Images) A ...

GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the likes of Moderna and BioNTech. The recombinant protein vaccine, dubbed ...

Vaccines are one of the most important medical inventions of modern times that have saved and enhanced innumerable lives around the world. Despite the technological advances in vaccine design and ...

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...

Lysine supplements are considered safe under most circumstances. Patients with severe renal or hepatic disease should avoid increased lysine intake due to the potential for interstitial damage in both ...

Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020. (HealthDay News) — The incidence and prevalence of genital ...